Markets:

Overview

News

Currencies

International

Treasuries

Zai Lab Limited - American Depositary Shares (NQ:ZLAB)

20.59 +0.26 (+1.28%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Zai Lab Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday ↗

March 27, 2025

Via Benzinga

Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting

March 26, 2025

From Zai Lab Limited

Via Business Wire

Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer

March 12, 2025

From Zai Lab Limited

Via Business Wire

Earnings Scheduled For February 27, 2025 ↗

February 27, 2025

Via Benzinga

Why Zai Lab (ZLAB) Stock Is Trading Higher ↗

November 15, 2024

Zai Lab shares are trading higher by 4% during Friday's session. The company priced a $200 million public offering.

Via Benzinga

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

Zai Lab Announces Participation in Investor Conferences in March 2025

March 03, 2025

From Zai Lab Limited

Via Business Wire

NovoCure Q4 EPS Misses, Revenue Matches ↗

February 27, 2025

NovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges.

Via The Motley Fool

Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates

February 27, 2025

From Zai Lab Limited

Via Business Wire

Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday ↗

February 18, 2025

Via Benzinga

Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025

January 28, 2025

From Zai Lab Limited

Via Business Wire

Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)

January 22, 2025

From Zai Lab Limited

Via Business Wire

Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia

January 17, 2025

From Zai Lab Limited

Via Business Wire

Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer

January 15, 2025

From Zai Lab Limited

Via Business Wire

Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore

January 10, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore

January 10, 2025

From Zai Lab Limited

Via Business Wire

Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate

January 09, 2025

From Zai Lab Limited

Via Business Wire

Zai Lab Announces Participation in Investor Conference in January 2025

December 12, 2024

From Zai Lab Limited

Via Business Wire

Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025? ↗

December 05, 2024

Via The Motley Fool

NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients ↗

December 02, 2024

NovoCure and Zai Lab report PANOVA-3 trial success with TTFields therapy, achieving significant survival benefits for pancreatic cancer patients.

Via Benzinga

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

December 02, 2024

From Zai Lab

Via Business Wire

Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China’s National Reimbursement Drug List

November 27, 2024

From Zai Lab Limited

Via Business Wire

Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)

November 21, 2024

From Zai Lab

Via Business Wire

Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares

November 18, 2024

From Zai Lab Limited

Via Business Wire

Despegar.com, Zai Lab, Bloom Energy And Other Big Stocks Moving Higher On Friday ↗

November 15, 2024

Via Benzinga

Zai Lab Announces Pricing of Public Offering of American Depositary Shares

November 14, 2024

From Zai Lab Limited

Via Business Wire

Zai Lab Announces Proposed Public Offering of American Depositary Shares

November 13, 2024

From Zai Lab Limited

Via Business Wire

Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates

November 12, 2024

From Zai Lab Limited

Via Business Wire

Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

November 11, 2024

From Zai Lab Limited

Via Business Wire

Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China

October 29, 2024

From Zai Lab Limited

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.